Imaging-guided hyperstimulation analgesia in low back pain

Miguel Gorenberg1,2
Kobi Schwartz3
1 Department of Nuclear Medicine, B’nai Zion Medical Center, Haifa, Israel; 2 The Rappaport Faculty of Medicine, Technion – Israel Institute of Technology, Haifa, Israel; 3 Department of Physical Therapy, B’nai Zion Medical Center, Haifa, Israel

Abstract: Low back pain in patients with myofascial pain syndrome is characterized by painful active myofascial trigger points (ATPs) in muscles. This article reviews a novel, noninvasive modality that combines simultaneous imaging and treatment, thus taking advantage of the electrodermal information available from imaged ATPs to deliver localized neurostimulation, to stimulate peripheral nerve endings (Aδ fibers) and in turn, to release endogenous endorphins. “Hyperstimulation analgesia” with localized, intense, low-rate electrical pulses applied to painful ATPs was found to be effective in 95% patients with chronic nonspecific low back pain, in a clinical validation study.

Keywords: myofascial, noninvasive, electrical, impedance

Introduction

Low back pain (LBP) is one of the most common complaints in the Western society.1 2 Ninety percent of the population in the United States suffer from low back pain at one or multiple points in time in their lifetime.3

Although LBP is a common chronic pain syndrome, in most cases a specific diagnosis cannot be established. It can arise due to spinal injury, spinal disc problems, osteoarthritis, spinal stenosis, compression fractures, spinal tumors, etc.3

Nonsteroidal anti-inflammatory drugs (NSAIDS) are generally used for acute LBP. Opioids are the alkaloid analgesics used for the treatment of moderate to severe pain syndromes. These opioids work on the μ, κ, and α receptors in the central nervous system;4 however, due to the wide presence of these receptors in the body, opioids not only suppress the noxious stimuli effects, but also have undesirable side effects.5,6 The concerns arising from the use of analgesic medications have increased the interest in nonpharmacological therapies for LBP. Nonpharmacological treatment modalities for pain relief include heat, cold, acupuncture, electrotherapy, and massage.7 The use of cold and hot methods has been shown to cause tissue and nerve injury.8–10 Among the electrotherapy modalities are transcutaneous electrical nerve stimulation (TENS) with various pulse modulation, electroacupuncture, and percutaneous electrical nerve stimulation (PENS).11–13 Unfortunately, these modalities go amiss with respect to their provided duration and magnitude of analgesia. Study of TENS has produced results with limited statistical significance,14 and the American Academy of Neurology has advised against the use of TENS in chronic LBP, stating that the strongest evidence indicates that it is ineffective for this syndrome.15
One accepted explanation for LBP symptoms is that patients have myofascial pain syndrome, a condition characterized by painful active myofascial trigger points (ATPs) in muscles.16,17

**ATP pathophysiology**

In the last 10–15 years, much clinical and basic science research into ATPs has been published, including epidemiological, diagnostic, therapeutic, and pathophysiological studies.17–21 The pathogenesis of ATPs is probably related to sensitized sensory peripheral free nerve endings (nociceptors) associated with dysfunctional endplates.16 In a histological study, small nerve fibers were commonly found near the sensitive ATPs.22 Therefore, the sensitive loci in the region of muscle ATPs are probably related to sensitized nerve fibers (nociceptors).

Local pain could be explained by the tissue ischemia resulting from prolonged muscle contraction, with accumulation of acids and chemicals such as serotonin, histamine, kinins, and prostaglandins.23

Studies have suggested that the development of ATPs is dependent on an integrative mechanism in the spinal cord. When the input from the nociceptors in an original receptive field (pain from ATPs) persists, central sensitization in the spinal cord may develop, and the receptive field corresponding to the original dorsal horn neuron may be expanded (referred pain). Through this mechanism, new “satellite ATPs” may develop in the referred zone of the original ATPs.16

“Hyperstimulation analgesia” of ATPs

Common treatments of ATPs typically include minimally invasive intervention, such as injections with local anesthetics, corticosteroids, botulinum toxin, or dry needling.24 Serious complications, although of rare occurrence, have been reported (eg, pneumothorax, hematoma, intravascular injection of local anesthetics, and intrathecal injections).25

“Hyperstimulation analgesia” is an alternative modality, in which localized, intense, low-rate electrical pulses are applied to small surface areas at ATP locations to stimulate peripheral nerve endings (Aδ fibers), thus causing the release of endogenous endorphins.26,27 Hyperstimulation analgesia has been investigated in several controlled studies, showing a positive response in 87% of patients.26–28 Considerable evidence suggests that this type of neurostimulation analgesia is achieved through the activation of extra-segmental antinociceptive mechanisms, which accelerate the release of endogenous endorphins, serotonin, and cortisol.27,31–34

**Identification of ATPs**

While the most common physical finding of ATPs has been considered the palpation of a hypersensitive nodule of muscle fiber of harder-than-normal consistency, the identification of such nodule appears to be very dependent on the subjective experience of the physician. There is no accepted reference standard for the clinical diagnosis of ATPs, and data on the reliability of physical examination are conflicting, and a 2009 review of nine studies examining the reliability of ATP diagnosis found that physical examination could not be recommended as reliable for the diagnosis of ATPs.24 Attempts to confirm the presence of myofascial trigger points using magnetic resonance elastography have been described.33 Recently, Sikdar et al have tried to use ultrasound to visualize and characterize ATPs.34 They found that ATPs appeared as focal, hypoechoic regions of elliptical shape, with a size of 0.16 cm.36

The presence of ATPs causes a localized decrease in skin resistance compared with the surrounding area.37,38 The hypoxic state in the pain area increases nociceptors and other sensitizing substances in the area, and this biochemical change induces greater blood flow and secretion from sweat glands, via stimulation of the autonomic nervous system.39 These physiologic differences may account for acute variations in electrodermal measurements at the pathologic site. ATPs are defined as small-diameter (3–4 mm), circumscribed, low-skin-resistance areas.38 Localized decrease in skin resistance is frequently associated with clinical ATPs that are richly innervated by myelinated Aδ fibers40,41 the smallest in diameter (0.2–1.5 μm) and most commonly present myelinated axons in peripheral nerves. Their extremely small size prevents their identification by any imaging modality.38

Electrical skin impedance measurements are considered to be vulnerable to certain sources of imprecision, including instrument error resulting from the size, pressure, and the duration of probe application as well as from local skin conditions, such as variable thickness, hydration, and integrity of the stratum corneum.38,42

**Auto-targeting hyperstimulation of painful ATPs**

The hyperstimulation analgesia procedure is not extensively utilized in the clinical setting due to the necessity of locating appropriate ATPs. This necessity requires previous knowledge of the potential locations and the identification of ATPs associated with LBP and makes such treatments time consuming and cumbersome.26–28 Some devices offer the capability of measuring skin impedance for the location of
The effectiveness of the Soleve™ system was investigated in 19 patients diagnosed with nonspecific chronic LBP.\(^4^4\) Fifteen of the patients were female (79%), and four were men (21%), with a mean age of 52.1 ± 10.8 years. The protocol consisted of six treatment sessions, 2−4 days apart. Each session included a 1-minute, automatic impedance screening, followed by a 20-minute treatment. The primary outcome measurement consisted of changes in pain intensity, as measured on a 100 mm-long pain visual analog scale (VAS) obtained at enrollment, pre-, and 2 hours posttreatment. The mean ± standard deviation (SD) baseline VAS score for all patients was 61 ± 14 mm (Figure 4). Following treatment, VAS scores decreased by 39 ± 17 mm (\(P = 0.001\)) compared with the baseline scores. Notably, the VAS scores of all but one patient decreased by more than 20 mm after the fourth treatment, representing a marked improvement in 95% of enrolled patients.

**Clinical validation**

The effectiveness of the Soleve™ system was investigated in 19 patients diagnosed with nonspecific chronic LBP.\(^4^4\) Fifteen of the patients were female (79%), and four were men (21%), with a mean age of 52.1 ± 10.8 years. The protocol consisted of six treatment sessions, 2−4 days apart. Each session included a 1-minute, automatic impedance screening, followed by a 20-minute treatment. The primary outcome measurement consisted of changes in pain intensity, as measured on a 100 mm-long pain visual analog scale (VAS) obtained at enrollment, pre-, and 2 hours posttreatment. The mean ± standard deviation (SD) baseline VAS score for all patients was 61 ± 14 mm (Figure 4). Following treatment, VAS scores decreased by 39 ± 17 mm (\(P < 0.001\)) compared with the baseline scores. Notably, the VAS scores of all but one patient decreased by more than 20 mm after the fourth treatment, representing a marked improvement in 95% of enrolled patients.
Conclusion
A novel, noninvasive, image-guided, targeted neurostimulation modality that combines impedance imaging to locate ATPs and treatment based on the image analysis was found very effective clinically in 95% of patients after a series of four treatments. This promising result warrants future investigation and randomized, controlled, longitudinal studies in the treatment of LBP.

Acknowledgment
This paper was supported by a grant from Nervomatrix, Israel.

Disclosure
Dr Gorenberg is a stockholder at Nervomatrix, Israel. The authors report no other conflicts of interest in this work.

References